Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $672.6 million.

  • Ptc Therapeutics' Cash & Equivalents rose 2787.37% to $672.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $672.6 million, marking a year-over-year increase of 2787.37%. This contributed to the annual value of $779.7 million for FY2024, which is 3126.39% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Cash & Equivalents stood at $672.6 million, which was up 2787.37% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Cash & Equivalents peaked at $1.5 billion during Q1 2025, and registered a low of $104.4 million during Q3 2022.
  • Over the past 5 years, Ptc Therapeutics' median Cash & Equivalents value was $208.4 million (recorded in 2023), while the average stood at $431.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 5626.01% in 2021, then soared by 22738.59% in 2024.
  • Ptc Therapeutics' Cash & Equivalents (Quarter) stood at $189.7 million in 2021, then surged by 47.5% to $279.8 million in 2022, then soared by 112.27% to $594.0 million in 2023, then skyrocketed by 31.26% to $779.7 million in 2024, then dropped by 13.73% to $672.6 million in 2025.
  • Its Cash & Equivalents stands at $672.6 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.5 billion for Q1 2025.